Original Research
Published on 16 Aug 2022
Comprehensive bibliometric analysis of sirtuins: Focus on sirt1 and kidney disease
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.966786
- 5,225 views
- 2 citations
Type at least 3 characters
604 articles
Articles
Original Research
Published on 16 Aug 2022
Total extract of Abelmoschus manihot L. alleviates uric acid-induced renal tubular epithelial injury via inhibition of caspase-8/caspase-3/NLRP3/GSDME signaling
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.907980
- 5,761 views
- 10 citations
Original Research
Published on 16 Aug 2022
Sappanone a prevents diabetic kidney disease by inhibiting kidney inflammation and fibrosis via the NF-κB signaling pathway
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.953004
- 3,831 views
- 16 citations
Original Research
Published on 15 Aug 2022
Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.829630
- 4,787 views
- 8 citations
Review
Published on 12 Aug 2022
TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.929262
- 9,372 views
- 46 citations
Review
Published on 11 Aug 2022
Molecular mechanisms and physiological functions of autophagy in kidney diseases
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.974829
- 4,415 views
- 5 citations
Systematic Review
Published on 11 Aug 2022
Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.929169
- 3,786 views
- 12 citations
Review
Published on 09 Aug 2022
Traditional Chinese herbs and natural products in hyperuricemia-induced chronic kidney disease
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.971032
- 8,082 views
- 26 citations
Review
Published on 08 Aug 2022
Traditional Chinese Medicine in Treating Primary Podocytosis: From Fundamental Science to Clinical Research
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.932739
- 3,952 views
- 1 citation
Original Research
Published on 03 Aug 2022
Activation of TRPC6 by AngⅡ Induces Podocyte Injury and Participates in Proteinuria of Nephrotic Syndrome
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.915153
- 4,854 views
- 10 citations
Systematic Review
Published on 25 Jul 2022
Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.917532
- 4,557 views
- 7 citations
Original Research
Published on 22 Jul 2022
Class IIa histone deacetylase inhibition ameliorates acute kidney injury by suppressing renal tubular cell apoptosis and enhancing autophagy and proliferation
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.946192
- 3,416 views
- 7 citations
Original Research
Published on 22 Jul 2022
Yishen Huashi Granules Ameliorated the Development of Diabetic Nephropathy by Reducing the Damage of Glomerular Filtration Barrier
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.872940
- 4,997 views
- 12 citations
Original Research
Published on 18 Jul 2022
Pharmacological Inhibition of STING/TBK1 Signaling Attenuates Myeloid Fibroblast Activation and Macrophage to Myofibroblast Transition in Renal Fibrosis
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.940716
- 8,065 views
- 16 citations
Review
Published on 18 Jul 2022
Traditional Chinese Medicine in the Treatment of Chronic Kidney Diseases: Theories, Applications, and Mechanisms
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.917975
- 61,807 views
- 34 citations
Original Research
Published on 14 Jul 2022
Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.938391
- 5,018 views
- 24 citations